These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 31580253)
21. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338 [TBL] [Abstract][Full Text] [Related]
22. The frequency of adverse drug reaction related admissions according to method of detection, admission urgency and medical department specialty. Brvar M; Fokter N; Bunc M; Mozina M BMC Clin Pharmacol; 2009 May; 9():8. PubMed ID: 19409112 [TBL] [Abstract][Full Text] [Related]
23. Interest of pharmacoepidemiology for the study of anticoagulants. Bagheri H Therapie; 2019 Apr; 74(2):245-248. PubMed ID: 30683443 [TBL] [Abstract][Full Text] [Related]
25. Risk factors of vitamin K antagonist overcoagulation. Marie I; Leprince P; Menard JF; Tharasse C; Levesque H QJM; 2012 Jan; 105(1):53-62. PubMed ID: 21880698 [TBL] [Abstract][Full Text] [Related]
26. Safety and effectiveness of direct oral anticoagulants versus vitamin K antagonists: results from 3 Italian regions. Kirchmayer U; Narduzzi S; Mayer F; Tuccori M; Leoni O; Belleudi V; Di Martino M; Lallo A; Addis A; Davoli M Recenti Prog Med; 2019 Apr; 110(4):195-202. PubMed ID: 31066365 [TBL] [Abstract][Full Text] [Related]
27. Suspected adverse drug reaction reports with oral anticoagulants in Portugal: a pharmacovigilance study. Caldeira D; Rodrigues R; Abreu D; Anes AM; Rosa MM; Ferreira JJ Expert Opin Drug Saf; 2018 Apr; 17(4):339-345. PubMed ID: 29463153 [TBL] [Abstract][Full Text] [Related]
28. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants. Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158 [TBL] [Abstract][Full Text] [Related]
29. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients Undergoing Cardioversion for Atrial Fibrillation: a Systematic Review and Meta-analysis. Gupta S; Um KJ; Pandey A; McIntyre WF; Ivanova M; Allahverdi Y; Agahi P; Pandya F; Lopez A; Sachdeva A; Whitlock RP; Belley-Cote EP Cardiovasc Drugs Ther; 2019 Jun; 33(3):339-352. PubMed ID: 31011880 [TBL] [Abstract][Full Text] [Related]
30. Adverse drug reactions (ADRs) associated with hospital admissions - elderly female patients are at highest risk. Hofer-Dueckelmann C; Prinz E; Beindl W; Szymanski J; Fellhofer G; Pichler M; Schuler J Int J Clin Pharmacol Ther; 2011 Oct; 49(10):577-86. PubMed ID: 21961482 [TBL] [Abstract][Full Text] [Related]
31. Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation. Trujillo TC; Dobesh PP; Crossley GH; Finks SW Pharmacotherapy; 2019 Jan; 39(1):94-108. PubMed ID: 30548542 [TBL] [Abstract][Full Text] [Related]
32. Non-bleeding Adverse Events with the Use of Direct Oral Anticoagulants: A Sequence Symmetry Analysis. Maura G; Billionnet C; Coste J; Weill A; Neumann A; Pariente A Drug Saf; 2018 Sep; 41(9):881-897. PubMed ID: 29714004 [TBL] [Abstract][Full Text] [Related]
33. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital. Geer MI; Koul PA; Tanki SA; Shah MY J Pharmacol Toxicol Methods; 2016; 81():323-34. PubMed ID: 27109493 [TBL] [Abstract][Full Text] [Related]
34. Adverse drug reactions leading to urgent hospital admission in an elderly population: prevalence and main features. Pedrós C; Formiga F; Corbella X; Arnau JM Eur J Clin Pharmacol; 2016 Feb; 72(2):219-26. PubMed ID: 26546335 [TBL] [Abstract][Full Text] [Related]
35. Adverse Drug Reactions in a Tertiary Care Emergency Medicine Ward - Prevalence, Preventability and Reporting. Rydberg DM; Holm L; Engqvist I; Fryckstedt J; Lindh JD; Stiller CO; Asker-Hagelberg C PLoS One; 2016; 11(9):e0162948. PubMed ID: 27622270 [TBL] [Abstract][Full Text] [Related]
36. Adaptation and validation of an adverse drug reaction preventability score for bleeding due to vitamin K antagonists. Liabeuf S; Masmoudi K; Scailteux LM; Moragny J; Masson H; Brnet-Dufour V; Andrejak M; Gras-Champel V Medicine (Baltimore); 2016 Sep; 95(39):e4762. PubMed ID: 27684801 [TBL] [Abstract][Full Text] [Related]
37. Prevalence, clinical features and avoidability of adverse drug reactions as cause of admission to a geriatric unit: a prospective study of 1756 patients. Franceschi M; Scarcelli C; Niro V; Seripa D; Pazienza AM; Pepe G; Colusso AM; Pacilli L; Pilotto A Drug Saf; 2008; 31(6):545-56. PubMed ID: 18484788 [TBL] [Abstract][Full Text] [Related]
38. Acute subdural hematoma in patients on oral anticoagulant therapy: management and outcome. Won SY; Dubinski D; Bruder M; Cattani A; Seifert V; Konczalla J Neurosurg Focus; 2017 Nov; 43(5):E12. PubMed ID: 29088960 [TBL] [Abstract][Full Text] [Related]
39. Reversal Agents for the Direct Oral Anticoagulants. Ansell JE Hematol Oncol Clin North Am; 2016 Oct; 30(5):1085-98. PubMed ID: 27637309 [TBL] [Abstract][Full Text] [Related]
40. Intracranial complications after minor head injury (MHI) in patients taking vitamin K antagonists (VKA) or direct oral anticoagulants (DOACs). Riccardi A; Spinola B; Minuto P; Ghinatti M; Guiddo G; Malerba M; Lerza R Am J Emerg Med; 2017 Sep; 35(9):1317-1319. PubMed ID: 28400068 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]